Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications

References

• Abbott WM, Snow M, Eckersley S, et al. (2013). Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFalpha Fab fragment and human TNFalpha. Biosci Rep, 33, e00060
   Google Scholar
• Ali T, Kaitha S, Mahmood S, et al. (2013). Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf, 5, 79–99
   PubMedGoogle Scholar
• Anfinsen CB. (1972). The formation and stabilization of protein structure. Biochem J, 128, 737–49
   PubMed Web of Science ®Google Scholar
• Århem K. (1989). Maasai food symbolism: the cultural connotations of milk, meat, and blood in the pastoral maasai diet. Anthropos, 84, 1–23
   Web of Science ®Google Scholar
• Ashcroft GS, Jeong MJ, Ashworth JJ, et al. (2012). Tumor necrosis factor-alpha (TNF-alpha) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen, 20, 38–49
   PubMed Web of Science ®Google Scholar
• Asteria CR, Ficari F, Bagnoli S, et al. (2006). Treatment of perianal fistulas in Crohn’s disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol, 41, 1064–72
   PubMed Web of Science ®Google Scholar
• Atreya R, Neumann H, Neufert C, et al. (2014). In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med, 20, 313–18
   PubMed Web of Science ®Google Scholar
• Attia EA, Belal DM, El Samahy MH, El Hamamsy MH. (2014). A pilot trial using topical regular crystalline insulin vs. aqueous zinc solution for uncomplicated cutaneous wound healing: impact on quality of life. Wound Repair Regen, 22, 52–7
   PubMed Web of Science ®Google Scholar
• Balsari AL, Morelli D, Menard S, et al. (1994). Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J, 8, 226–30
   PubMed Web of Science ®Google Scholar
• Balsari A, Rumio C, Morelli D, et al. (2001). Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. Br J Cancer, 85, 1964–7
   PubMed Web of Science ®Google Scholar
• Barde C, Laffitte E, Campanelli A, et al. (2011). Intralesional infliximab in noninfectious cutaneous granulomas: three cases of necrobiosis lipoidica. Dermatology, 222, 212–16
   PubMed Web of Science ®Google Scholar
• Barekzi NA, Felts AG, Poelstra KA, et al. (2002). Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections. Pharm Res, 19, 1801–7
   PubMed Web of Science ®Google Scholar
• Barnes GL, Doyle LW, Hewson PH, et al. (1982). A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet, 319, 1371–3
   Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. (2011). Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA, 305, 1460–8
   PubMed Web of Science ®Google Scholar
• Bashshur ZF, Bazarbachi A, Schakal A, et al. (2006). Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol, 142, 1–9
   PubMed Web of Science ®Google Scholar
• Berdugo M, Larsen IV, Abadie C, et al. (2012). Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application. Antimicrob Agents Chemother, 56, 1390–402
   PubMed Web of Science ®Google Scholar
• Berghman LR, Abi-Ghanem D, Waghela SD, Ricke SC. (2005). Antibodies: an alternative for antibiotics? Poult Sci, 84, 660–6
   PubMed Web of Science ®Google Scholar
• Berry JD, Gaudet RG. (2011). Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol, 28, 489–501
   PubMed Web of Science ®Google Scholar
• Bhol KC, Tracey DE, Lemos BR, et al. (2013). AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis, 19, 2273–81
   PubMed Web of Science ®Google Scholar
• Bhol KC, Erlich EC, Keane DM, et al. (2014). Effects of AVX-470m, an oral polyclonal anti-TNF antibody, on survival and biomarkers in a murine model of gastrointestinal acute radiation syndrome. Gastroenterology, 146, S–352
   Google Scholar
• Blum PM, Phelps DL, Ank BJ, et al. (1981). Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants. Pediatr Res, 15, 1256–60
   PubMed Web of Science ®Google Scholar
• Boirie Y, Dangin M, Gachon P, et al. (1997). Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci USA, 94, 14930–5
   PubMed Web of Science ®Google Scholar
• Boushaba R, Kumpalume P, Slater NKH. (2003). Kinetics of whole serum and prepurified IgG digestion by pepsin for F(ab′)2 manufacture. Biotechnol Prog, 19, 1176–82
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, et al. (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339, 89–91
   PubMed Web of Science ®Google Scholar
• Brereton HM, Taylor SD, Farrall A, et al. (2005). Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol, 89, 1205–9
   PubMed Web of Science ®Google Scholar
• Brown WE, Wold F. (1973). Alkyl isocyanates as active-site-specific reagents for serine proteases. Identification of the active-site serine as the site of reaction. Biochemistry, 12, 835–40
   PubMed Web of Science ®Google Scholar
• Brunser O, Espinoza J, Figueroa G, et al. (1992). Field trial of an infant formula containing anti-rotavirus and anti-Escherichia coli milk antibodies from hyperimmunized cows. J Pediatr Gastroenterol Nutr, 15, 63–72
   PubMed Web of Science ®Google Scholar
• Brussow H, Hilpert H, Walther I, et al. (1987). Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol, 25, 982–6
   PubMed Web of Science ®Google Scholar
• Burek-Kozlowska A, Morell A, Hunziker T. (1994). Topical immunoglobulin G in atopic dermatitis. Int Arch Allergy Immunol, 104, 104–6
   PubMed Web of Science ®Google Scholar
• Carlander D, Kollberg H, Wejaker PE, Larsson A. (2000). Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res, 21, 1–6
   PubMed Web of Science ®Google Scholar
• Casadevall A. (1999). Passive antibody therapies: progress and continuing challenges. Clin Immunol, 93, 5–15
   PubMed Web of Science ®Google Scholar
• Casadevall A. (2002). Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis, 8, 833–41
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. (2012). Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe, 11, 447–56
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. (2004). Passive antibody therapy for infectious diseases. Nat Rev Microbiol, 2, 695–703
   PubMed Web of Science ®Google Scholar
• Casswall TH, Sarker SA, Faruque SM, et al. (2000). Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: a double-blind, placebo-controlled, clinical trial. Scand J Gastroenterol, 35, 711–18
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol, 157, 220–33
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 10, 301–16
   PubMed Web of Science ®Google Scholar
• Charles F, Camilleri M, Phillips SF, et al. (1995). Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clin Proc, 70, 113–18
   PubMed Web of Science ®Google Scholar
• Church D, Elsayed S, Reid O, et al. (2006). Burn wound infections. Clin Microbiol Rev, 19, 403–34
   PubMed Web of Science ®Google Scholar
• Code of Federal Regulations. (2014). Title 21: food and drugs. Washington, DC: Government Printing Office, USA
   Google Scholar
• Collins PJ, Houghton LA, Read NW, et al. (1991). Role of the proximal and distal stomach in mixed solid and liquid meal emptying. Gut, 32, 615–19
   PubMed Web of Science ®Google Scholar
• Copelan EA, Bechtel TP, Klein JP, et al. (1994). Controlled trial of orally administered immunoglobulin following bone marrow transplantation. Bone Marrow Transplant, 13, 87–91
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. Science, 342, 1432–3
   PubMed Web of Science ®Google Scholar
• Crabb JH. (1998). Antibody-based immunotherapy of cryptosporidiosis. Adv Parasitol, 40, 121–49
   PubMed Web of Science ®Google Scholar
• Cumberlege GI. (1911). Administration of serum by the mouth. Br Med J, 2, 108
   PubMedGoogle Scholar
• Cunningham-Rundles C, Zhuo Z, Griffith B, Keenan J. (1992). Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation. J Immunol Methods, 152, 177–90
   PubMed Web of Science ®Google Scholar
• da Cunha AP, Weiner HL. (2012). Induction of immunological tolerance by oral anti-CD3. Clin Dev Immunol, 2012, e425021
   PubMedGoogle Scholar
• Davidson GP, Whyte PB, Daniels E, et al. (1989). Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet, 2, 709–12
   PubMed Web of Science ®Google Scholar
• Degen LP, Phillips SF. (1996). Variability of gastrointestinal transit in healthy women and men. Gut, 39, 299–305
   PubMed Web of Science ®Google Scholar
• den Hoed CM, de Vries AC, Mensink PB, et al. (2011). Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial. Can J Gastroenterol, 25, 207–13
   PubMed Web of Science ®Google Scholar
• Dixon FJ, Kuhns W, Weigle WO, Taylor P. (1959). The lack of absorption of ingested bovine antibody in humans. J Immunol, 83, 437–41
   PubMed Web of Science ®Google Scholar
• Dumoulin M, Conrath K, Van Meirhaeghe A, et al. (2002). Single-domain antibody fragments with high conformational stability. Protein Sci, 11, 500–15
   PubMed Web of Science ®Google Scholar
• Dvorackova K, Rabiskova M, Gajdziok J, et al. (2010). Coated capsules for drug targeting to proximal and distal part of human intestine. Acta Pol Pharm, 67, 191–9
   PubMed Web of Science ®Google Scholar
• Ebina T, Sato A, Umezu K, et al. (1985). Prevention of rotavirus infection by oral administration of cow colostrum containing antihumanrotavirus antibody. Med Microbiol Immunol, 174, 177–85
   PubMed Web of Science ®Google Scholar
• Eibl MM, Wolf HM, Furnkranz H, Rosenkranz A. (1988). Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med, 319, 1–7
   PubMed Web of Science ®Google Scholar
• Ermolenko DN, Zherdev AV, Dzantiev BB. (2004). Antibodies as specific chaperones. Biochemistry (Mosc), 69, 1233–8
   PubMed Web of Science ®Google Scholar
• Evans CH, Kraus VB, Setton LA. (2014). Progress in intra-articular therapy. Nat Rev Rheumatol, 10, 11–22
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Geypens B, Luypaerts A, et al. (1998). Digestibility of cooked and raw egg protein in humans as assessed by stable isotope techniques. J Nutr, 128, 1716–22
   PubMed Web of Science ®Google Scholar
• Farag N, Mahran L, Abou-Aisha K, El-Azizi M. (2013). Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur J Clin Microbiol Infect Dis, 32, 1149–60
   PubMed Web of Science ®Google Scholar
• Faria AM, Weiner HL. (2005). Oral tolerance. Immunol Rev, 206, 232–59
   PubMed Web of Science ®Google Scholar
• FDA. (2002). New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist, 67, 37988–98
   PubMedGoogle Scholar
• Felts AG, Giridhar G, Grainger DW, Slunt JB. (1999). Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Burns, 25, 415–23
   PubMed Web of Science ®Google Scholar
• Felts AG, Grainger DW, Slunt JB. (2000). Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection. J Trauma, 49, 873–8
   PubMedGoogle Scholar
• Ferrara N, Damico L, Shams N, et al. (2006). Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina, 26, 859–70
   PubMed Web of Science ®Google Scholar
• Ferrari G, Bignami F, Giacomini C, et al. (2013). Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci, 54, 1680–8
   PubMed Web of Science ®Google Scholar
• Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. (2009). Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int, 29, 961–5
   PubMed Web of Science ®Google Scholar
• Fisher BA, Keat A. (2006). Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis? J Rheumatol, 33, 1934–5
   PubMed Web of Science ®Google Scholar
• Florescu DF, Hill LA, McCartan MA, Grant W. (2008). Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr Transplant, 12, 372–5
   PubMed Web of Science ®Google Scholar
• Florescu DF, Hermsen ED, Kwon JY, et al. (2011). Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients? Pediatr Transplant, 15, 718–21
   PubMed Web of Science ®Google Scholar
• Fong AH, Lai TY. (2013). Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging, 8, 467–83
   PubMed Web of Science ®Google Scholar
• Fontana A, de Laureto PP, Spolaore B, et al. (2004). Probing protein structure by limited proteolysis. Acta Biochim Pol, 51, 299–321
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. (2013). Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol, 108, 1268–76
   PubMed Web of Science ®Google Scholar
• Fransen MF, van der Sluis TC, Ossendorp F, et al. (2013). Controlled local delivery of CTLA-4 blocking antibody induces CD8 + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res, 19, 5381–9
   PubMed Web of Science ®Google Scholar
• Furrer E, Berdugo M, Stella C, et al. (2009). Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci, 50, 771–8
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. (2011). Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford), 50, 124–31
   PubMed Web of Science ®Google Scholar
• Gomez HF, Miller MJ, Trachy JW, et al. (1999). Intradermal anti-loxosceles Fab fragments attenuate dermonecrotic arachnidism. Acad Emerg Med, 6, 1195–202
   PubMed Web of Science ®Google Scholar
• Guarino A, Canani RB, Russo S, et al. (1994). Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics, 93, 12–16
   PubMed Web of Science ®Google Scholar
• Hammarstrom V, Smith CI, Hammarstrom L. (1993). Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet, 341, 1036
   PubMedGoogle Scholar
• Hammarstrom L, Gardulf A, Hammarstrom V, et al. (1994). Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev, 139, 43–70
   PubMed Web of Science ®Google Scholar
• Hansen S. (2013). Product discovery and development. Topical antibodies. BioCentury, 9, 7
   Google Scholar
• Harmsen MM, De Haard HJ. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 77, 13–22
   PubMed Web of Science ®Google Scholar
• Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, et al. (2006). Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol, 72, 544–51
   PubMed Web of Science ®Google Scholar
• Hilpert H, Brussow H, Mietens C, et al. (1987). Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis, 156, 158–66
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711–23
   PubMed Web of Science ®Google Scholar
• Horie K, Horie N, Abdou AM, et al. (2004). Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci, 87, 4073–9
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335–42
   PubMed Web of Science ®Google Scholar
• Husby S, Mestecky J, Moldoveanu Z, et al. (1994). Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol, 152, 4663–70
   PubMed Web of Science ®Google Scholar
• Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. (2011). Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem, 286, 8961–76
   PubMed Web of Science ®Google Scholar
• Hussack G, Tanha J. (2010). Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel), 2, 998–1018
   PubMed Web of Science ®Google Scholar
• Hussack G, Mackenzie CR, Tanha J. (2012). Characterization of single-domain antibodies with an engineered disulfide bond. Methods Mol Biol, 911, 417–29
   PubMedGoogle Scholar
• Ibekwe VC, Fadda HM, McConnell EL, et al. (2008). Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res, 25, 1828–35
   PubMed Web of Science ®Google Scholar
• Ibrahim SM, Rahman AK, Isoda R, et al. (2008). In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine, 26, 2073–80
   PubMed Web of Science ®Google Scholar
• Imoto T, Yamada H, Ueda T. (1986). Unfolding rates of globular proteins determined by kinetics of proteolysis. J Mol Biol, 190, 647–9
   PubMed Web of Science ®Google Scholar
• Jackson JE, Kopecki Z, Adams DH, Cowin AJ. (2012). Flii neutralizing antibodies improve wound healing in porcine preclinical studies. Wound Repair Regen, 20, 523–36
   PubMed Web of Science ®Google Scholar
• Jemmerson R, Paterson Y. (1986). Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science, 232, 1001–4
   PubMed Web of Science ®Google Scholar
• Jones RGA, Landon J. (2002). Enhanced pepsin digestion: a novel process for purifying antibody F(ab′)2 fragments in high yield from serum. J Immunol Methods, 263, 57–74
   PubMed Web of Science ®Google Scholar
• Jones RGA, Landon J. (2003). A protocol for ‘enhanced pepsin digestion’: a step by step method for obtaining pure antibody fragments in high yield from serum. J Immunol Methods, 275, 239–50
   PubMed Web of Science ®Google Scholar
• Jones RGA, Marks JD. (2013). Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol, 62, 828–35
   PubMed Web of Science ®Google Scholar
• Jones RGA, Lee L, Landon J. (1999). The effects of specific antibody fragments on the ‘irreversible’ neurotoxicity induced by Brown snake (Pseudonaja) venom. Br J Pharmacol, 126, 581–4
   PubMed Web of Science ®Google Scholar
• Kanfer EJ, Abrahamson G, Taylor J, et al. (1994). Severe rotavirus-associated diarrhoea following bone marrow transplantation: treatment with oral immunoglobulin. Bone Marrow Transplant, 14, 651–2
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet, 49, 493–507
   PubMed Web of Science ®Google Scholar
• Kelly CP, Chetham S, Keates S, et al. (1997). Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother, 41, 236–41
   PubMed Web of Science ®Google Scholar
• Kitamura K, Takahashi T, Kotani T, et al. (1992). Local administration of monoclonal antibody-drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer. Cancer Res, 52, 6323–8
   PubMed Web of Science ®Google Scholar
• Klager AJ, Buchi ER, Osusky R, et al. (1993). Topical immunoglobulins for epithelial herpes simplex keratitis. Ophthalmologica, 207, 78–81
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Ametani A, Yamauchi K, Kaminogawa S. (1991). Differences in defining residues relevant to antibody binding by ELISA and proteolysis protection at the level of peptide antigenic determinants. Biochim Biophys Acta, 1077, 11–18
   PubMed Web of Science ®Google Scholar
• Kollberg H, Carlander D, Olesen H, et al. (2003). Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol, 35, 433–40
   PubMed Web of Science ®Google Scholar
• Kopecki Z, Ruzehaji N, Turner C, et al. (2013). Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. J Invest Dermatol, 133, 1008–16
   PubMed Web of Science ®Google Scholar
• Kovacs-Nolan J, Mine Y. (2012). Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol, 3, 163–82
   PubMed Web of Science ®Google Scholar
• Kovacs-Nolan J, Mine Y. (2005). Microencapsulation for the gastric passage and controlled intestinal release of immunoglobulin Y. J Immunol Methods, 296, 199–209
   PubMed Web of Science ®Google Scholar
• Kozuch PL, Hanauer SB. (2008). Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol, 14, 354–77
   PubMed Web of Science ®Google Scholar
• Krizova D, Vokrojova M, Liehneova K, Studeny P. (2014). Treatment of corneal neovascularization using anti-VEGF bevacizumab. J Ophthalmol, 2014, e178132
   PubMed Web of Science ®Google Scholar
• Krogdahl A, Holm H. (1981). Soybean proteinase inhibitors and human proteolytic enzymes: selective inactivation of inhibitors by treatment with human gastric juice. J Nutr, 111, 2045–51
   PubMed Web of Science ®Google Scholar
• Kumpalume P, Boushaba R, Jones RGA, Slater NKH. (2002). Facile F(ab′)2 manufacturing: strategies for the production of snake antivenoms. Food Bioprod Process, 80, 88–97
   Web of Science ®Google Scholar
• Lalazar A, Loyter A. (1979). Involvement of spectrin in membrane fusion: induction of fusion in human erythrocyte ghosts by proteolytic enzymes and its inhibition by antispectrin antibody. Proc Natl Acad Sci USA, 76, 318–22
   PubMed Web of Science ®Google Scholar
• Landon J, Smith DS. (2003). Merits of sheep antisera for antivenom manufacture. Toxin Rev, 22, 15–22
   Web of Science ®Google Scholar
• Larsson A, Carlander D. (2003). Oral immunotherapy with yolk antibodies to prevent infections in humans and animals. Ups J Med Sci, 108, 129–40
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ting PT, Koo JY. (2005). Psoriasis treatment: traditional therapy. Ann Rheum Dis, 64, 83–6
   Web of Science ®Google Scholar
• Lichtlen P, Lam TT, Nork TM, et al. (2010). Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci, 51, 4738–45
   PubMed Web of Science ®Google Scholar
• Liu F, Basit AW. (2010). A paradigm shift in enteric coating: achieving rapid release in the proximal small intestine of man. J Control Release, 147, 242–5
   PubMed Web of Science ®Google Scholar
• Liu F, Moreno P, Basit AW. (2010). A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract. Eur J Pharm Biopharm, 74, 311–15
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Johnson JP, Winkelstein JA, Yolken RH. (1985). Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest, 76, 2362–7
   PubMed Web of Science ®Google Scholar
• MacLennan C, Dunn G, Huissoon AP, et al. (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet, 363, 1509–13
   PubMed Web of Science ®Google Scholar
• Madsen JL. (1992). Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci, 37, 1548–53
   PubMed Web of Science ®Google Scholar
• Mahe S, Roos N, Benamouzig R, et al. (1996). Gastrojejunal kinetics and the digestion of [15N]beta-lactoglobulin and casein in humans: the influence of the nature and quantity of the protein. Am J Clin Nutr, 63, 546–52
   PubMed Web of Science ®Google Scholar
• Manca F, Fenoglio D, Li PG, et al. (1991). Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med, 173, 37–48
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Levy R. (2013a). Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res, 19, 5261–3
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, et al. (2013b). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest, 123, 2447–63
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Caux C, Levy R. (2014). Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res, 20, 1747–56
   PubMed Web of Science ®Google Scholar
• Marasco WA, Sui J. (2007). The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol, 25, 1421–34
   PubMed Web of Science ®Google Scholar
• Mattila E, Anttila VJ, Broas M, et al. (2008). A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis, 40, 702–8
   PubMed Web of Science ®Google Scholar
• Meddeb-Mouelhi F, Bouhaouala-Zahar B, Benlasfar Z, et al. (2003). Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon, 42, 785–91
   PubMed Web of Science ®Google Scholar
• Mayberry JF, Lobo A, Ford AC, Thomas A. (2013). NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther, 37, 195–203
   PubMed Web of Science ®Google Scholar
• Meyer T, Ullrich R, Zeitz M. (2012). Oral tolerance induction in humans. Exp Mol Pathol, 93, 449–54
   PubMed Web of Science ®Google Scholar
• MHRA. (2014). Rules and guidance for pharmaceutical manufacturers and distributors 2014 the orange guide. Crown, UK
   Google Scholar
• Mietens C, Keinhorst H, Hilpert H, et al. (1979). Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins. Eur J Pediatr, 132, 239–52
   PubMed Web of Science ®Google Scholar
• Mojaverian P, Ferguson RK, Vlasses PH, et al. (1985). Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology, 89, 392–7
   PubMed Web of Science ®Google Scholar
• Morelli D, Menard S, Colnaghi MI, Balsari A. (1996). Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res, 56, 2082–5
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology, 113, 2002–12
   PubMed Web of Science ®Google Scholar
• Neri P, Tokoro S, Kobayashi R, et al. (2011). Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases. PLoS One, 6, e26526
   PubMed Web of Science ®Google Scholar
• Newcombe C, Newcombe AR. (2007). Antibody production: polyclonal-derived biotherapeutics. J Chromatogr B, 848:2–7
   PubMed Web of Science ®Google Scholar
• NICE. (2008). Adalimumab for the treatment of adults with psoriasis (TA146). Available from: http://www.nice.org.uk/guidance/TA146 [last accessed 20 Jul 2014]
   Google Scholar
• NICE. (2009). Rheumatoid arthritis (CG79). Available from: http://www.nice.org.uk/guidance/CG79 [last accessed 20 Jul 2014]
   Google Scholar
• Nikas SN, Temekonidis TI, Zikou AK, et al. (2004). Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis, 63, 102–3
   PubMed Web of Science ®Google Scholar
• Nilsson E, Kollberg H, Johannesson M, et al. (2007). More than 10 years’ continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J Med Food, 10, 375–8
   PubMed Web of Science ®Google Scholar
• Nilsson E, Larsson A, Olesen HV, et al. (2008). Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol, 43, 892–9
   PubMed Web of Science ®Google Scholar
• Nord J, Ma P, DiJohn D, et al. (1990). Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS, 4, 581–4
   PubMed Web of Science ®Google Scholar
• Numan SC, Veldkamp P, Kuijper EJ, et al. (2007). Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut, 56, 888–9
   PubMed Web of Science ®Google Scholar
• Ohtani T, Habu M, Khanal A, et al. (2012). Local effects of intra-articular injection of anti-rabbit tumor necrosis factor alpha monoclonal antibody in antigen-induced arthritis of the rabbit temporomandibular joint. J Oral Pathol Med, 41, 96–105
   PubMed Web of Science ®Google Scholar
• Ohtani S, Shirasu K, Ogawara K, et al. (2003). Evaluation of inhibitory activity of casein on proteases in rat intestine. Pharm Res, 20, 611–17
   PubMed Web of Science ®Google Scholar
• Okhuysen PC, Chappell CL, Crabb J, et al. (1998). Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum. Clin Infect Dis, 26, 1324–9
   PubMed Web of Science ®Google Scholar
• Ottiger M, Thiel MA, Feige U, et al. (2009). Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci, 50, 779–86
   PubMed Web of Science ®Google Scholar
• Pacyna J, Siwek K, Terry SJ, et al. (2001). Survival of rotavirus antibody activity derived from bovine colostrum after passage through the human gastrointestinal tract. J Pediatr Gastroenterol Nutr, 32, 162–7
   PubMed Web of Science ®Google Scholar
• Pant N, Hultberg A, Zhao Y, et al. (2006). Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis, 194, 1580–8
   PubMed Web of Science ®Google Scholar
• Paton DM. (1906). Serum therapy by the mouth. Br Med J, 1, 1032
   PubMedGoogle Scholar
• Petschow BW, Talbott RD. (1994). Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr, 19, 228–35
   PubMed Web of Science ®Google Scholar
• Petsoglou C, Balaggan KS, Dart JK, et al. (2013). Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol, 97, 28–32
   PubMed Web of Science ®Google Scholar
• Pinho E, Grootveld M, Soares G, Henriques M. (2014). Cyclodextrin-based hydrogels toward improved wound dressings. Crit Rev Biotechnol, 34, 328–37
   PubMed Web of Science ®Google Scholar
• Playford RJ, Woodman AC, Clark P, et al. (1993). Effect of luminal growth factor preservation on intestinal growth. Lancet, 341, 843–8
   PubMed Web of Science ®Google Scholar
• Pocklington T, Jeffery J. (1969). Competition of two substrates for a single enzyme. A simple kinetic theorem exemplified by a hydroxy steroid dehydrogenase reaction. Biochem J, 112, 331–4
   PubMed Web of Science ®Google Scholar
• Poelstra KA, Barekzi NA, Slunt JB, et al. (2000). Surgical irrigation with pooled human immunoglobulin G to reduce post-operative spinal implant infection. Tissue Eng, 6, 401–11
   PubMedGoogle Scholar
• Porter RR. (1959). The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem J, 73, 119–26
   PubMed Web of Science ®Google Scholar
• Powers JC, Harley AD, Myers DV. (1977). Subsite specificity of porcine pepsin. Adv Exp Med Biol, 95, 141–57
   PubMedGoogle Scholar
• Rahman S, Higo-Moriguchi K, Htun KW, et al. (2012). Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine, 30, 4661–9
   PubMed Web of Science ®Google Scholar
• Rao RK, Baker RD, Baker SS. (1998). Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides, 19, 495–504
   PubMed Web of Science ®Google Scholar
• Reichert JM. (2011). Antibody-based therapeutics to watch in 2011. MAbs, 3, 76–99
   PubMed Web of Science ®Google Scholar
• Reichert JM. (2012). Marketed therapeutic antibodies compendium. MAbs, 4, 413–15
   PubMed Web of Science ®Google Scholar
• Reseland JE, Holm H, Jacobsen MB, et al. (1996). Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J Nutr, 126, 634–42
   PubMed Web of Science ®Google Scholar
• Roos N, Mahe S, Benamouzig R, et al. (1995). 15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine. J Nutr, 125, 1238–44
   PubMed Web of Science ®Google Scholar
• Roy FH, Fraunfelder FW, Fraunfelder FT. (2008). Roy and Fraunfelder’s current ocular therapy. 6th ed. London: Saunders Imprint
   Google Scholar
• Ruzehaji N, Kopecki Z, Melville E, et al. (2014). Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes. Diabetologia, 57, 402–12
   PubMed Web of Science ®Google Scholar
• Salemi S, Markovic M, Martini G, D’Amelio R. (2014). The expanding role of therapeutic antibodies. Int Rev Immunol. Published online ahead of print 28 January 2014, doi:10.3109/08830185.2013.863304
   PubMed Web of Science ®Google Scholar
• Sandin LC, Eriksson F, Ellmark P, et al. (2014a). Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology, 3, e27614
   PubMed Web of Science ®Google Scholar
• Sandin LC, Orlova A, Gustafsson E, et al. (2014b). Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res, 2, 80–90
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. (2004). Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med, 350, 876–85
   PubMed Web of Science ®Google Scholar
• Sarker SA, Casswall TH, Juneja LR, et al. (2001). Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr, 32, 19–25
   PubMed Web of Science ®Google Scholar
• Sarker SA, Jakel M, Sultana S, et al. (2013). Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. Gastroenterology, 145, 740–8
   PubMed Web of Science ®Google Scholar
• Schade R, Calzado EG, Sarmiento R, et al. (2005). Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine. Altern Lab Anim, 33, 129–54
   PubMed Web of Science ®Google Scholar
• Schlamowitz M, Peterson LU. (1959). Studies on the optimum pH for the action of pepsin on “native” and denatured bovine serum albumin and bovine hemoglobin. J Biol Chem, 234, 3137–45
   PubMed Web of Science ®Google Scholar
• Schmidt P, Wiedemann V, Kuhlmann R, et al. (1989). Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases. II. In vitro studies on gastric and enteric digestion of egg yolk antibodies specific against pathogenic Escherichia coli strains. Zentralbl Veterinarmed B, 36, 619–28
   PubMedGoogle Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. (2007). Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med, 357, 239–50
   PubMed Web of Science ®Google Scholar
• Scott AM, Allison JP, Wolchok JD. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunol, 12, 1–8
   Google Scholar
• Shone C, Landon J. (2014). Antibodies to Clostridium difficile toxins. Patent US8709428 B2, USA
   Google Scholar
• Shone C, Roberts A, Landon J. (2013). Therapies for preventing or suppressing Clostridium difficile infection. Patent application US20130004561 A1
   Google Scholar
• Splittgerber AG. (1983). Simplified treatment of two-substrate enzyme kinetics. J Chem Educ, 60, 651–5
   Web of Science ®Google Scholar
• Steinbrook R. (2006). The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med, 355, 1409–12
   PubMed Web of Science ®Google Scholar
• Stevens NE, Fraser CK, Alsharifi M, et al. (2013). An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT is functionally superior to Freund’s adjuvant. PLoS One, 8, e68895
   PubMedGoogle Scholar
• Stevenson W, Cheng SF, Dastjerdi MH, et al. (2012). Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf, 10, 67–83
   PubMed Web of Science ®Google Scholar
• Streit M, Beleznay Z, Braathen LR. (2006). Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J, 3, 171–9
   PubMedGoogle Scholar
• Suckau D, Kohl J, Karwath G, et al. (1990). Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping. Proc Natl Acad Sci USA, 87, 9848–52
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nomura S, Masaoka T, et al. (2004). Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther, 20, 185–92
   PubMed Web of Science ®Google Scholar
• Syed A, Cross RK, Flasar MH. (2013). Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol, 108, 583–93
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Link H, et al. (1988). Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med, 318, 1240–3
   PubMed Web of Science ®Google Scholar
• Tacket CO, Binion SB, Bostwick E, et al. (1992). Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg, 47, 276–83
   PubMed Web of Science ®Google Scholar
• Tappenden P, Jones R, Paisley S, Carroll C. (2007). Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess, 11, 1–4
   PubMed Web of Science ®Google Scholar
• Taxonera C, Schwartz DA, Garcia-Olmo D. (2009). Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol, 15, 4263–72
   PubMed Web of Science ®Google Scholar
• Teh YH, Kavanagh TA. (2010). High-level expression of Camelid nanobodies in Nicotiana benthamiana. Transgenic Res, 19, 575–86
   PubMed Web of Science ®Google Scholar
• Teich N, Klugmann T. (2014). Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis, 8, 85–6
   PubMed Web of Science ®Google Scholar
• Thakral S, Thakral NK, Majumdar DK. (2013). Eudragit: a technology evaluation. Expert Opin Drug Deliv, 10, 131–49
   PubMed Web of Science ®Google Scholar
• Thiel MA, Coster DJ, Standfield SD, et al. (2002). Penetration of engineered antibody fragments into the eye. Clin Exp Immunol, 128, 67–74
   PubMed Web of Science ®Google Scholar
• Thiel MA, Wild A, Schmid MK, et al. (2013). Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology, 120, 1403–8
   PubMed Web of Science ®Google Scholar
• Tjellstrom B, Stenhammar L, Magnusson KE, Sandqvist T. (1997). Oral immunoglobulin treatment in Crohn’s disease. Acta Paediatr, 86, 221–3
   PubMed Web of Science ®Google Scholar
• Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. (1993). Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet, 341, 701–2
   PubMed Web of Science ®Google Scholar
• Tollemar J, Gross N, Dolgiras N, et al. (1999). Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant, 23, 283–90
   PubMed Web of Science ®Google Scholar
• Tonelli F, Giudici F, Asteria CR. (2012). Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn’s disease: a pilot study. Dis Colon Rectum, 55, 870–5
   PubMed Web of Science ®Google Scholar
• Urech DM, Feige U, Ewert S, et al. (2010). Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF alpha single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis, 69, 443–9
   PubMed Web of Science ®Google Scholar
• van Dissel JT, de Groot N, Hensgens CM, et al. (2005). Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol, 54, 197–205
   PubMed Web of Science ®Google Scholar
• Vandenbroucke K, de Haard H, Beirnaert E, et al. (2010). Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol, 3, 49–56
   PubMed Web of Science ®Google Scholar
• von Behring E. (1901). Nobel Lecture: Serum therapy in therapeutics and medical science. Available from Nobelprize.org. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-lecture.html [last accessed 1 Jul 2014]
   Google Scholar
• Waaga-Gasser AM, Gasser M, Stock M, et al. (2009). Oral immunoglobulin induces mononuclear cell apoptosis in patients suffering from idiopathic chronic pain syndrome: results from a pilot study. Int J Clin Pharmacol Ther, 47, 421–33
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther, 84, 548–58
   PubMed Web of Science ®Google Scholar
• Warny M, Fatimi A, Bostwick EF, et al. (1999). Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut, 44, 212–17
   PubMed Web of Science ®Google Scholar
• Weiner C, Pan Q, Hurtig M, et al. (1999). Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol, 116, 193–205
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, et al. (2008). Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther, 28, 1122–6
   PubMed Web of Science ®Google Scholar
• Wicher K, Zabek J, Wicher V. (1992). Effect of passive immunization with purified specific or cross-reacting immunoglobulin G antibodies against Treponema pallidum on the course of infection in guinea pigs. Infect Immunol, 60, 3217–23
   PubMed Web of Science ®Google Scholar
• Williams KA, Irani YD, Klebe S. (2013). Novel therapeutic approaches for corneal disease. Discov Med, 15, 291–9
   PubMedGoogle Scholar
• Worledge KL, Godiska R, Barrett TA, Kink JA. (2000). Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci, 45, 2298–305
   PubMed Web of Science ®Google Scholar
• Xian CJ, Shoubridge CA, Read LC. (1995). Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. J Endocrinol, 146, 215–25
   PubMed Web of Science ®Google Scholar
• Xu ZQ, Flavin MT, Flavin J. (2014). Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs, 23, 163–82
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Zaidi T, Pier GB, Priebe GP. (2012). Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immunol, 80, 3706–12
   PubMed Web of Science ®Google Scholar